Temozolomide (TMZ) CAS 85622-93-1 Assay 99.0% ~ 101.0% API Factory High Tsabta
Samar da Temozolomide da Matsakaici masu alaƙa:
Temozolomide CAS: 85622-93-1
4 (5)-Amino-5 (4) -Imidazolecarboxamide CAS: 360-97-4
5 (4)-Amino-4 (5) -Imidazolecarboxamide Hydrochloride CAS: 72-40-2
| Sunan Sinadari | Temozolomide |
| Makamantu | 3,4-Dihydro-3-Methyl-4-Oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-Carboxamide |
| Lambar CAS | 85622-93-1 |
| Lambar CAT | RF-API29 |
| Matsayin Hannun jari | A cikin Hannun jari, Ma'aunin samarwa Har zuwa Ton |
| Tsarin kwayoyin halitta | Saukewa: C6H6N6O2 |
| Nauyin Kwayoyin Halitta | 194.15 |
| Matsayin narkewa | 212 ℃ dec. |
| Alamar | Ruifu Chemical |
| Abu | Ƙayyadaddun bayanai |
| Bayyanar | Fari zuwa Hasken Foda |
| Ganewa | By IR, HPLC |
| Ragowar Magani | Dimethyl sulfoxide ≤0.50% |
| Abubuwa masu alaƙa | |
| Rashin tsabta AIC | ≤0.10% |
| Tsaftace Guda Daya | ≤0.10% |
| Sauran Abubuwan da ba a sani ba | ≤0.30% |
| Jimlar ƙazanta | ≤0.30% |
| Karfe masu nauyi | ≤10ppm |
| Asara akan bushewa | ≤0.50% |
| Ragowa akan Ignition | ≤0.10% |
| Assay | 99.0% ~ 101.0% (HPLC akan busasshiyar tushe) |
| Matsayin Gwaji | Matsayin Kasuwanci |
| Amfani | Sinadarin Magunguna Mai Aiki (API) |
Kunshin: Bottle, Aluminum tsare jakar, Kwali drum, 25kg / Drum, ko bisa ga abokin ciniki ta bukata.
Yanayin Ajiya:Ajiye a cikin kwantena da aka rufe a wuri mai sanyi da bushe;Kare daga haske, danshi da kamuwa da kwari.
Shanghai Ruifu Chemical Co., Ltd. shine babban masana'anta kuma mai samar da Temozolomide (CAS: 85622-93-1) tare da inganci mai inganci.Temozolomide (TMZ) wakili ne na alkylating na baka da ake amfani dashi don magance Glioblastoma Multiforme (GBM) da Astrocytomas, Metastatic Melanoma.
Temozolomide shine farkon ingantaccen maganin imidazole da tetrazine-class anticancer wanda ke cikin ƙarni na biyu na wakili na alkylating tare da aikin antitumor ba tare da kunna metabolism na hanta ba bayan gudanar da baki.Yana da alaƙa da sauƙi shiga ta hanyar shingen kwakwalwar jini, haƙuri mai kyau kuma ba a sanya shi tare da wasu magunguna masu guba ba, kuma yana da tasirin synergistic tare da radiotherapy wanda ya dace don magance sake dawowar glioma mara kyau bayan jiyya na al'ada irin su glioblastoma multiforme ciwace-ciwacen daji ko astrocytoma degenerative.Yana da magani na farko don maganin melanoma metastatic.
Cibiyar Cancer Research UK Group ce ta fara haɗa Temozolomide, sannan a tura shi zuwa Kamfanin Schering-Plough (Amurka) don haɓakawa.Yana da sabon tsarin sinadarai kuma nasa ne na nau'in imidazole hudu.A cikin 1999, an amince da shi don shiga kasuwa a cikin EU da Amurka inda aka ba da izini a cikin Amurka galibi don jiyya na layi na biyu na glioblastoma multiforme da gliomas tauraro mai lalacewa da alamun da aka yarda da EU don magance haɓaka ko sake dawowa glioblastoma multiforme wanda ya riga ya kasance batun maganin al'ada.Tasirin temozolomide akan maganin glioblastoma multiforme ya sami ƙarin karbuwa a Turai.
